Aggressive natural killer-cell leukemia (ANKL) is a rare neoplasm characterized by peripheral blood and bone marrow involvement of malignant NK cells. This neoplasm has a rapidly progressive clinical course and a fatal outcome 491
Background : Aggressive natural killer-cell leukemia (ANKL) is a rare neoplasm characterized by systemic proliferation of NK cells. However, the differential diagnosis of NK lymphoproliferative disorders is difficult because of the absence of a distinct diagnostic hallmark. Therefore, to identify diagnostic markers for ANKL, we analyzed the clinical data and laboratory findings obtained for 20 patients with ANKL.
Methods : From January 2000 to July 2007, 20 patients were diagnosed with ANKL on the basis of bone marrow studies. We retrospectively analyzed the clinical features and laboratory findings, including the complete blood count, Epstein-Barr virus status, immunophenotype, and the cytogenetic results.
Results : The subjects included 6 women and 14 men (median age, 44 yr; range, 2-70 yr). Cytogenetic studies were performed in 18 patients, and karyotypic abnormalities were observed in 9 patients (50%). None of the cytogenetic abnormalities were constantly observed in all the patients. However, 6q abnormalities were observed in 4 patients (4/18, 22%). The immunophenotype of the leukemic NKcells was cytoplasmic CD3 + , surface CD3 -, CD16/56 + , CD2 + , and CD5 -. Notably, the CD7 antigen was absent in 10 patients (50%). When the CD7 loss was combined with cytogenetic abnormalities, clonal markers could be identified in 75% of the ANKL cases.
Conclusions : The CD7 antigen loss was frequently observed in our series of ANKL patients. In conjunction with the cytogenetic findings, this characteristic immunophenotypic finding can serve as a reliable marker for the timely diagnosis of ANKL. Therefore, immunophenotypic analysis of CD7 expression should be included in the diagnosis of NK cell neoplasms. (Korean J Lab Med 2009;29:491-6) [1, 2] . The clinical manifestations of ANKL include fever, marked hepatosplenomegaly, lymphoadenopathy, coagulopathy, multiorgan failure, and a strong association with Epstein-Barr virus (EBV) [2] [3] [4] [5] . ANKL is more prevalent in Asia than in Western countries [2, 3] ; the prevalence of the disease is correlated with the distribution of EBV [6, 7] .
In Korea, aggressive NK/T cell lymphoma accounts for 33% of all aggressive lymphomas [8] .
Since ANKL has a fulminant course, a rapid and accurate diagnosis of the disease is extremely important. However, the available information on this disease is limited and the diagnosis is even more complicated in the cases with a low number of malignant cells. There are no validated clonal markers for diagnosing ANKL, except for cytogenetic abnormalities. The absence of a diagnostic hallmark has complicated the differential diagnosis from indolent NK cell lymphoproliferative disorders, including hemophagocytic lymphohistiocytosis. ANKL and benign NK cell disorders may show similar morphologic, immunophenotypic, and genetic characteristics (large granular lymphocytes, surface CD3 -/CD56 +/-, and germline T-cell receptor genes), and the diagnosis of ANKL is primarily dependent on the clinical features [9] . Therefore, to identify diagnostic markers for ANKL, we analyzed the clinical data and laboratory findings obtained from bone marrow studies in ANKL patients. 
MATERIALS AND METHODS

Patients
Immunophenotypic analysis using flow cytometry and immunohistochemistry
The leukemic cells were typically large granular lymphocytes with pale or lightly basophilic cytoplasm that conta- 
Cytogenetic analysis
Statistics
Statistical analysis was performed using MedCalc (Med- 
DISCUSSION
There was a considerable immunophenotypic difference among the series of ANKL patients in our study. The CD7 antigen was absent in 10 patients (10/20; 50%), and the proportion of CD7 -ANKL patients in our study was much higher than that reported in previous studies. In a review of the studies published from 1966 to 2003, Ruskova et al. [3] reported that CD7 expression was absent in 35.5% of 73 ANKL patients, while Suzuki et al. [10] reported that CD7 expression was absent in only 26% of 22 Japanese patients.
The immunophenotype for ANKL originated from mature NK cells is CD34 -, CD33 -, CD56 + ; the cells also express Tcell-associated antigens such as CD2 and CD7 [11, 12] . The 40-kD glycoprotein CD7 is one of the earliest antigens appearing during the development of the T-and NK-cell lineage [13, 14] , and this antigen is considered to play a role in cell adhesion and activation [15] . CD7 expression is the first sign of differentiation of the hematopoietic stem cells committed to the NK lineage, and the expression of this antigen correlates with the various properties of the NK cells, including increased cloning efficiency, increased sensitivity to low-dose interleukin (IL-2), increased expression of IL2Rb, and decreased requirement for stromal contact [14] . CD7 delivers a pro-apoptotic signal during the T-cell death induced by galectin-1; therefore, CD7-negative T cells may be resistant to apoptosis [16] . Although the absence of CD7 expression is considered to be a marker for the diagnosis of T cell leukemia/lymphomas such as Sezary cell leukemia and adult T cell leukemia associated with human T-cell leukemia virus-type 1 (HTLV-1) [17] , it is not a very specific marker for malignant T cells because CD7 loss is rather frequently observed in normal T-cell development [18] . However, CD7 is associated with the differentiation of NK cells from uncommitted bone marrow (BM) progenitors, and this antigen is highly expressed in normal immature and mature NK cells [14] . Hence, the absence of CD7 expression in ANKL cases can have important implications on the diagnosis of ANKL. The CD7 + group and the CD7groups did not show any significant differences in the clinical findings, including the survival rates. Therefore, the impact of CD7 expression on clinical manifestation and prognosis may be insignificant.
The differential diagnosis of ANKL and other NK/T cell malignancies were also important. Surface CD3 and CD16/56
antibodies have been analyzed together to identify and determine the proportion of NK cells (surface CD3 -/CD16/56 + ). [21] [22] [23] . Therefore, the diagnostic value of determining the EBV status in these diseases is still debatable.
In the absence of a definite clonal marker, cytogenetic analysis has been the most important factor for the laboratory-based diagnosis of ANKL. However, no constant cytogenetic abnormalities have been identified in ANKL cases. Aberrations involving the chromosome 6q appear to be the most frequent cytogenetic abnormality [24] . None of the cytogenetic abnormalities were constantly observed in all the patients. However, there were 6q abnormalities in 4 cases and 7q abnormalities in 3 cases, including 2 cases with isochromosome 7, which is the most frequent abnormality for hepatosplenic T-cell lymphoma [25] . These abnormalities are not unique to ANKL, and half of the ANKL cases showed a normal karyotype; therefore, the diagnosis based solely on cytogenetic analysis is not sufficient to prove clonality in NK cell proliferation. CD7 expression was absent in all 3 cases of 6q deletion and all these cases showed an aggressive clinical outcome. However, a large-scale study of the correlation between 6q deletion and CD7 loss in ANKL is required to obtain any definitive conclusions.
In the present study, we report that the characteristic immunophenotypic findings, absence of CD7 antigen can be considered as reliable diagnostic markers for the timely diagnosis of ANKL. When the CD7 loss was combined with cytogenetic abnormalities, clonal markers could be identified in 75% of ANKL cases, compared to 50% being detected only by the cytogenetic results. Therefore, immunophenotypic analysis of CD7 expression should be included in the diagnosis of ANKL. This approach would be helpful for rapid and accurate diagnosis, thereby facilitating appropriate management of ANKL patients.
